Regeneron Pharmaceuticals, Inc. (REGN)

555.70
0.46 0.08
NASDAQ
Prev Close 555.24
Open 551.14
Day Low/High 542.15 / 556.46
52 Wk Low/High 271.37 / 664.64
Volume 678.21K
Exchange NASDAQ
Shares Outstanding 106.39B
Market Cap 60.11B
P/E Ratio 21.90
Div & Yield N.A. (N.A)
Cramer: Here's What to Embrace and What to Shun

Cramer: Here's What to Embrace and What to Shun

With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.

Amgen and Regeneron Expanding Anti-Cancer Research

Amgen and Regeneron Expanding Anti-Cancer Research

The two Big Pharma giants are looking for new ways to drive growth through anti-cancer treatments.

Cramer: What Are You Thinking? It Should Be Long Term

Cramer: What Are You Thinking? It Should Be Long Term

That may be the best way to get through the notorious month of August.

Jim Cramer: I’m Looking at the Biotechs

Jim Cramer: I’m Looking at the Biotechs

Utilities and other high yielding sectors are reaching overbought levels, so investors may want to rotate into biotechs, says Jim Cramer.

Regeneron Is Regenerating Lost Profits

Regeneron Is Regenerating Lost Profits

Investors should risk below $380 for now.

Cramer: Might Something Be Brewing in 3 Downtrodden Sectors?

Biotech, restaurants and retail have been left for dead but are showing signs of life today.

Regeneron Tries to Recover From Lows

Regeneron Tries to Recover From Lows

Prices pop today, but is this a reversal?

Regeneron May Cure the Market Blues

Regeneron May Cure the Market Blues

A potentially bullish pattern is setting up. 

How to Trade Regeneron's Pullback

How to Trade Regeneron's Pullback

Aggressive traders can go long REGN on the first up day.

Regeneron downgraded at Wells

Cramer: Here's Why Facebook's Stock Has Been Falling

Cramer: Here's Why Facebook's Stock Has Been Falling

Stocks like Facebook or Palo Alto Networks are expensive for the moment.

Cramer: See What Happens When Takeover Talk Gets Going?

Cramer: See What Happens When Takeover Talk Gets Going?

With Pfizer deal dead, Allergan is ready to go shopping.

Regeneron's Chart Has Degenerative Look

Regeneron's Chart Has Degenerative Look

The biopharmaceutical company's chart is still pointed lower. 

Jim Cramer Says Oracle Is Okay, But He Really Likes Salesforce.com

Jim Cramer Says Oracle Is Okay, But He Really Likes Salesforce.com

TheStreet’s Jim Cramer discussed the bear market in biotechs while answering viewer questions from social media on Friday.

Midday Report: Fox News Hits Record Profit; U.S. Stocks Waver

Midday Report: Fox News Hits Record Profit; U.S. Stocks Waver

U.S. stocks gave up earlier gains as the energy sector continued to sell off despite relatively stable crude prices on Tuesday.

Double Top Could Spell Double Trouble for Regeneron

Double Top Could Spell Double Trouble for Regeneron

The biopharmaceutical company is in for a deeper bear phase. 

Regeneron downgraded at Canaccord

Cramer: This Is Where I Say I Was Wrong

Cramer: This Is Where I Say I Was Wrong

My speculation on Fitbit and Alcoa didn't work out.

Jim Cramer Says Own Salesforce.com, Regeneron, First Solar

Jim Cramer Says Own Salesforce.com, Regeneron, First Solar

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer says Macy's should benefit from the cold weather and energy stocks are still 'too dangerous' to put money into.

Have a CIGAR, You'll Go Far in 2016

Have a CIGAR, You'll Go Far in 2016

5 biotech stocks that could outperform the overall market in 2016.

Jim Cramer on Why Netflix, Chipotle and Regeneron Soared During QE

Jim Cramer on Why Netflix, Chipotle and Regeneron Soared During QE

TheStreet looked at stocks that soared under the Federal Reserve’s QE program, and Jim Cramer explains why some shares performed better than others.

Don't Abandon the Biotech Ship

Don't Abandon the Biotech Ship

There's too much good out there.

Ailing Stocks Are Making a Recovery

Ailing Stocks Are Making a Recovery

Apple tops the list, but it has lots of company.

Jim Cramer Sees a Deal on Priceline Stock, Likes Weyerhaeuser

Jim Cramer Sees a Deal on Priceline Stock, Likes Weyerhaeuser

TheStreet's Jim Cramer said to buy Priceline (PCLN) on the dip Monday while answering viewer questions from the floor of the New York Stock Exchange.

This Acronym Really Stinks

This Acronym Really Stinks

Don't use it as a gauge of market strength.

Stocks Slightly Lower Amid Yellen's Rate-Hike Hints

Stocks are trading in a relatively narrow range, but are slightly down after Federal Reserve chair Janet Yellen hinted at a possible December rate hike. Still, her remarks are only having a minor impact on the market given the many Fed "head fakes" ...

Rotation Is Enough to Make Your Head Spin

Rotation Is Enough to Make Your Head Spin

Bad news isn't always a bad thing.

Anatomy of a Rally: Simpler Than You Think

Anatomy of a Rally: Simpler Than You Think

Understanding why stocks act the way they do.

Grasping at Growth: The Hunt Is On

Grasping at Growth: The Hunt Is On

Once again, buyers are going for the gusto.

5 Biotech Stocks With Bullish Charts That Will Push the Sector Higher

5 Biotech Stocks With Bullish Charts That Will Push the Sector Higher

The common thread in these 5 names is the bullish divergence between the lower lows in price and the higher low in the momentum study.